|
Israel's BrainStorm names
Biogen senior executive Kern as COO
Send a link to a friend
[March 06, 2017] TEL
AVIV (Reuters) - Israel's BrainStorm Cell Therapeutics, which is
developing an adult stem cell treatment for patients with amyotrophic
lateral sclerosis (ALS), on Monday named Ralph Kern as chief operating
officer.
|
|
Kern, who has also been named chief medical officer, joins
BrainStorm from Biogen, where he was senior vice president and head
of worldwide medical. At Biogen he helped define the company's
therapeutic area and scientific strategies for Alzheimer's disease,
multiple sclerosis, spinal muscular atrophy, Parkinson's,
neurodegeneration and hemophilia.
He was previously head of the neuroscience medical unit at Novartis
and global medical director of personalized genetic health at
Genzyme Corp.
BrainStorm is preparing to conduct a Phase 3 clinical trial for its
NurOwn treatment at multiple sites in the United States and Israel.
The company has said the advanced trial is expected to begin
enrolling patients in the second quarter.
"I am confident that BrainStorm will become the world leader in
adult stem cell therapies for neurodegenerative disorders," Kern
said.
(Reporting by Tova Cohen)
[to top of second column] |
[© 2017 Thomson Reuters. All rights
reserved.] Copyright 2017 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed. |
